(Q36945209)

17 August 2017

1 reference

title

The role of lipoprotein-associated phospholipase A2 as a marker for atherosclerosis (English)

1 reference

17 August 2017

1 reference

1 reference

Salim S Virani

1

1 reference

17 August 2017

Vijay Nambi

series ordinal

2

1 reference

17 August 2017

language of work or name

1 reference

1 August 2007

1 reference

Current Atherosclerosis Reports

17 August 2017

published in

1 reference

17 August 2017

volume

9

1 reference

17 August 2017

issue

2

1 reference

17 August 2017

page(s)

97-103

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-007-0004-9

17 August 2017

exact match

0 references

cites work

Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-007-0004-9

A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-007-0004-9

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-007-0004-9

Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia

21 January 2018

1 reference

12 December 2020

Plasma PAF acetylhydrolase in non-insulin dependent diabetes mellitus and obesity: effect of hyperinsulinemia and lovastatin treatment.

1 reference

12 December 2020

Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.

1 reference

12 December 2020

Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein

1 reference

12 December 2020

Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL-).

1 reference

12 December 2020

Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial

1 reference

12 December 2020

The effect of statin therapy on lipoprotein associated phospholipase A2 levels

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests

1 reference

12 December 2020

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

1 reference

12 December 2020

The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma

1 reference

12 December 2020

PLAC test for identification of individuals at increased risk for coronary heart disease.

1 reference

12 December 2020

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

1 reference

12 December 2020

Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values

1 reference

12 December 2020

Platelet-activating factor acetylhydrolases

1 reference

12 December 2020

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects

1 reference

12 December 2020

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

1 reference

12 December 2020

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern G

1 reference

12 December 2020

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study

1 reference

12 December 2020

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular events

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar

1 reference

12 December 2020

Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.

1 reference

12 December 2020

Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions

1 reference

12 December 2020

Inflammation and atherosclerosis

1 reference

12 December 2020

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

12 December 2020

Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles

1 reference

12 December 2020

Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans

1 reference

12 December 2020

Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase

1 reference

12 December 2020

C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study

1 reference

12 December 2020

Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress

1 reference

12 December 2020

Lipoprotein-associated PLA2 inhibition--a novel, non-lipid lowering strategy for atherosclerosis therapy

1 reference

12 December 2020

Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase

1 reference

12 December 2020

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

1 reference

12 December 2020

Isolation, Characterization, and Functional Assessment of Oxidatively Modified Subfractions of Circulating Low-Density Lipoproteins

1 reference

12 December 2020

Anti-inflammatory properties of a platelet-activating factor acetylhydrolase

1 reference

12 December 2020

Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe

1 reference

12 December 2020

Prediction of the risk of myocardial infarction from polymorphisms in candidate genes

1 reference

12 December 2020

Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes

1 reference

12 December 2020

Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses

1 reference

12 December 2020

Lp-PLA2 inhibitors (GlaxoSmithKline)

1 reference

12 December 2020

Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.

1 reference

12 December 2020

Coronary Calcification, Coronary Disease Risk Factors, C-Reactive Protein, and Atherosclerotic Cardiovascular Disease Events

1 reference

12 December 2020

Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

10.1007/S11883-007-0004-9

Identifiers

DOI

1 reference

17 August 2017

1 reference